US20130315985A1 - Process for preparing purified nucleic acid and the use thereof - Google Patents

Process for preparing purified nucleic acid and the use thereof Download PDF

Info

Publication number
US20130315985A1
US20130315985A1 US13938398 US201313938398A US2013315985A1 US 20130315985 A1 US20130315985 A1 US 20130315985A1 US 13938398 US13938398 US 13938398 US 201313938398 A US201313938398 A US 201313938398A US 2013315985 A1 US2013315985 A1 US 2013315985A1
Authority
US
Grant status
Application
Patent type
Prior art keywords
dna
preparation
obtain
filtrate
step
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US13938398
Inventor
Wolfgang Kuhne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Roche Diagnostics GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0091Purification or manufacturing processes for gene therapy compositions
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/10Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1003Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor
    • C12N15/1006Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers
    • C12N15/101Extracting or separating nucleic acids from biological samples, e.g. pure separation or isolation methods; Conditions, buffers or apparatuses therefor by means of a solid support carrier, e.g. particles, polymers by chromatography, e.g. electrophoresis, ion-exchange, reverse phase
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Abstract

The invention relates to a nucleic acid preparation with a content of below 1% protein, preferably below 0.1% protein, free of ethidium bromide, phenol, cesium chloride and detergents based on octyl phenol poly(ethylene glycol ether)n and with a content of below 1 EU/mg DNA of endotoxins. Said preparation is suitable as a drug particularly in gene therapy.

Description

  • This application is a divisional of 13/545,427, filed Jul. 10, 2012, which is a divisional of 13/197,225 filed Aug. 3, 2011, which is a divisional of 12/627,449 filed Nov. 30, 2009, which is a divisional 11/389,167 filed Mar. 27, 2006, which is a continuation of U.S. Ser. No. 10/771,371 filed Feb. 5, 2004, which is a divisional of U.S. Ser. No. 09/117,537 filed Aug. 4, 1998, now U.S. Pat. No. 6,750,333, which is a 35 USC 371 of PCT/EP97/00321 filed Jan. 24, 1997, which claims the benefit of EP96101628.4 filed Feb. 6, 1996, the disclosures of which are incorporated herein in their entirety by reference.
  • The invention concerns the preparation of purified nucleic acid and its use especially in gene therapy.
  • Replicatable nucleic acid is usually produced by amplifying replicatable plasmid DNA in gram-negative bacteria such as e.g. E. coli. After lysis of the biomass (usually alkaline lysis with lysozyme or ultrasound), it is centrifuged and the supernatant is shaken out with phenol. Subsequently an ultracentrifugation on a caesium chloride gradient is carried out (Birnboim & Doly, Nucleic Acid Res. 7 (1979) 1513-1523, Garger et al., Biochem. Biophys. Res. Comm. 117 (1983) 835-842). However, such preparations contain endotoxins, phenol, caesium chloride and/or ethidium bromide as a dye.
  • A further process is described in the QIAGEN® Plasmid Handbook (Qiagen Inc., Chatsworth, U.S.A.) and EP-B 0 268 946. According to this process the cell lysate obtained after a conventional lysis is chromatographed on QIAGEN®-TIP, which contains QIAGEN® resin (a support material based on silica). The disadvantage of this process is that DNA binding proteins are not completely detached from the DNA and therefore the purified plasmid fraction contains proteins and in particular endotoxins (from the membrane of the gram-negative host cells) in considerable amounts.
  • In another process after alkaline lysis of the E. coli biomass the centrifugation supernatant is chromatographed according to Birnboim & Doly under high salt conditions over anion exchange columns (e.g. Mono-Q, Source-Q from Pharmacia, Macroprep-Q from BioRad, Poros-Q from Perseptive Biosystems or HyperD-Q from Biosepra, cf. Chandra et.al., Analyt. Biochem. 203 (1992) 169-172; Dion et al., J. Chrom. 535 (1990) 127-147). Also in this case the purified plasmid fraction contains proteins and in particular endotoxins in considerable amounts.
  • In another process after alkaline lysis and subsequent phenol/chloroform extraction it is possible to chromatograph by gel filtration (McClung & Gonzales, Analyt. Biochem. 177 (1989) 378-382; Raymond et al., Analyt. Biochem. 173 (1988) 125-133). Even after this purification the plasmid preparation contains impurities and in particular phenol.
  • A process for the isolation and purification of nucleic acids for use in gene therapy is described in WO 95/21177 in which the purification is essentially carried out by centrifugation, filtration, affinity chromatography or chromatography on an inorganic chromatographic material with subsequent chromatography on an ion exchanger. An additional removal of endotoxins tan then be achieved according to WO 95/21177 when the nucleic acid is treated with an endotoxin removal buffer which contains 10% Triton®X100 and 40 mmol/l<MOPS buffer (3-morpholino-1-propanesulfonate buffer). A disadvantage of this process is that the nucleic acid purified in this manner contains impurities of Triton® and MOPS buffer. Although endotoxins can be removed by this process to a content of ca. 100 EU/mg DNA (Qiagen News 1/96, 3-5), it is not possible to remove endotoxins to a greater extent by this process.
  • However, for a therapeutic application such as for example for gene therapy a nucleic acid preparation is required which is as free as possible of all impurities (in particular substantially free of endotoxins). Above all the endotoxin content of plasmid preparations has been hitherto an unsolved problem as described for example by Cotten et al., Gene Therapy 1 (1994) 239-246. A reduced endotoxin content (ca. 100 EU/mg DNA) can only be achieved by the state of the art such as for example according to WO 95/21177 if the nucleic acids are treated with non-ionic detergents such as e.g. Triton (endotoxin removal buffer from WO 95/21177). However, Triton® has a biological action such as e.g. lung changes or reduction of blood pressure (Fiedler, “Lexikon der Hilfstoffe für Pharmazie und Kosmetik und angrenzende Gebiete (Band 9,3rd edition, 1989, Editio Cantor, DE)). The MOPS buffer which is additionally required also contains a substance that is problematic with regard to a therapeutic application.
  • The invention provides a nucleic acid preparation, preferably a plasmid DNA, of high purity in which endotoxins are substantially removed and preferably without ethidium bromide, phenol, caesium chloride, polymyxin or non-ionic detergents and also provides a simple and effective process for purifying such nucleic acids in particular for removing endotoxins.
  • The invention concerns a nucleic acid that can be replicated in gram-negative bacteria, preferably a plasmid DNA with a content of less than 1% protein, preferably less than 0.1% protein and a content of less than 1 EU/mg DNA, preferably 0.01-0.1 EU/mg DNA of endotoxins. This plasmid DNA is preferably free of ethidium bromide, phenol and caesium chloride, free of detergents based on octylphenolpoly(ethylene glycol ether)n such as Triton® detergents and also free of MOPS buffer substance and RNAse.
  • Amplification is understood as an increase in the copy number of a nucleic acid (in particular DNA and plasmid DNA) based on the replication of a vector. In this process numerous copies are produced from a template. A Vector is replicated which represents the nucleic acid or which contains the cloned nucleic acid.
  • A plasmid DNA is understood as an extrachromosomal DNA duplex molecule. The size of a DNA plasmid is usually 1 to more than 200 kb and one to several hundred copies are present in host cells. Plasmid DNA is usually amplified in gram-negative bacteria such as e.g. E.coli and subsequently isolated. Plasmids are often used to construct cloning vectors, for the transfection of prokaryotic and eukaryotic cells. A therapeutic use is of especial importance in connection with in vivo and ex vivo gene therapy. Plasmid DNA that is used therapeutically preferably has a length of 5 to 20 kb, particularly preferably 5-10 kb and is double-stranded. The plasmid DNA can be linearized or circularly closed. Preferably DNA is used that is essentially circularly closed.
  • Consequently the invention additionally concerns a pharmaceutical composition containing a nucleic acid according to the invention, preferably plasmid DNA, in a therapeutically effective amount and optionally additional pharmaceutical auxiliary substances, fillers or additives.
  • Endotoxins are lipopolysaccharides from gram-negative bacteria. Endotoxins can have a pyrogenic effect in mammals and induce an endotoxin shock. The main toxic component of endotoxins is lipid A, the polysaccharide moiety mediating the water solubility and the lipid moiety having the toxic effect. The biological effect of endotoxins in mammals are in particular a hypersensitization as well as other reactions which are accompanied by fever.
  • Plasmid DNA is amplified by standard methods in E. coli i.e. a gram-negative bacterium. After fermentation the biomass obtained in this process is lysed and the cells are lysed. In this process the endotoxins are released from the cell membrane. This means that after amplification of nucleic acids, in particular of plasmid DNA, in gram-negative bacteria and in particular in E. coli it is necessary to remove endotoxins if it is intended to use this plasmid DNA therapeutically.
  • Depending on the application doses of 50 μg to 10 mg and more are used or planned for a therapeutic application of replicatable nucleic acids, in particular of plasmid DNA. The dose amount depends on the disease and type of administration. In an aerosol, e.g. for the treatment of cystic fibrosis, doses of 400 μg and more are used. This applies likewise to plasmid DNA encapsulated in a lipid complex (e.g. in liposomes). In order to provide such amounts of replicatable nucleic acid that can be used therapeutically, it is necessary to produce the replicatable nucleic acid on a large scale. For this fermentation preparations are expedient with 1-5 kg biomass from which 1-5 g nucleic acid can be isolated.
  • The invention also concerns a process for the production of a plasmid DNA with a content of less than 1 EU/mg DNA, preferably 0.01-0.1 EU/mg DNA of endotoxins which is characterized in that plasmid DNA is replicated in gram-negative bacteria, the biomass is lysed and the soluble components are chromatographed on hydroxylapatite and subsequently the said plasmid DNA is isolated. Before chromatography on hydroxylapatite it is preferably to carry out an ion exchange chromatography which essentially removes RNA and foreign proteins. This can optionally remove further impurities and achieve a content of nucleic acid of less than 1% protein, preferably less than 0.1% protein, free of ethidium bromide, phenol and caesium chloride. Such a preparation is also preferably free of detergents based on octylphenol poly(ethylene glycol ether)n and MOPS buffer substance.
  • The process according to the invention enables numerous impurities to be avoided or removed which plasmid DNA contains if it is produced by a process familiar to a person skilled in the art. Above all it is surprisingly possible to drastically reduce the endotoxin content in a simple manner.
  • In the process according to the invention an outstanding removal of endotoxins is achieved by the chromatography with hydroxylapatite. This is all the more surprising since chromatography on hydroxylapatite is only used in the literature to separate DNA and RNA (Johnson & Ilan, Analyt. Biochem. 132 (1983) 20-25).
  • The chromatographic effect of hydroxylapatite is essentially based on the interaction between calcium2+ groups and the negative charge of the nucleic acid to be purified and to a lesser extent on the interaction of the nucleic acid to be purified with PO4 3− groups on the surface of crystalline hydroxylapatite (cf e.g. Protein Purification Methods, Ed. by Elv. Harries and S. Angal, Oxford University Press 1989, 238-244). Chromatography on hydroxylapatite can be essentially referred to as an ion exchanger step for nucleic acids in which the bound DNA cannot be eluted from the hydroxylapatite matrix by a simple increase of ionic strength (e.g. NaCl) but rather by increasing the concentration, preferably of phosphate or citrate, divalent metal ions and/or EDTA.
  • In the process according to the invention endotoxins and the nucleic acid to be purified are firstly bound to hydroxylapatite primarily via dipole-dipole interactions in the chromatography on hydroxylapatite (e.g. HA-ceramic, BioGel HPHT, Bio-Gel HT/HTP from Biorad DE, HA-Ultrogel from IBF or HA spheroidal from BDH, Macrosorb C from Sterling Organics). The equilibration is usually carried out at neutral pH in phosphate buffer. A denaturing agent is preferably added, as in the subsequent washing of the column. Surprisingly it is possible to displace the nucleic acid from its binding to hydroxylapatite with phosphate, citrate or calcium ions whereas the endotoxins remain bound. Instead of calcium, the displacement of the nucleic acid from its binding to hydroxylapatite can be achieved with other divalent metal ions which can replace calcium in the apatite such as e.g. Mg, Fe, Mn. For the elution the ion concentration is preferably 100 mmol/l or more. Ion concentrations between 100 and 500 mmol/l or 200 and 500 mmol/l are particularly preferred. A solution containing phosphate ions (e.g. phosphate buffer) is particularly preferably used. Before the elution (without denaturing agent) it is expedient to wash (with denaturing agent). It has turned out to be advantageous to for example use a phosphate of sulfate solution (100-200 mmol/l) to which a denaturing agent (e.g. urea or guanidine hydrochloride) has been added at a DNA-denaturing concentration (e.g. 6 mol/l urea).
  • In a preferred embodiment an ultrafiltration is additionally carried out after the chromatography on hydroxylapatite.
  • In order to produce the nucleic acid according to the invention the plasmids which represent or contain the nucleic acid are usually amplified in gram-negative bacterial cultures. Such methods are known to a person skilled in the art and are described for example by Sambrook et al. (1989), Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press and by F.M. Ausubel et al., eds. (1991), Current Protocols in Molecular Biology, Wiley Interscience, New York. For this the bacterial cultures which contain the plasmids are firstly subcultured and subsequently cultured in a suitable medium optionally with addition of a selection agent.
  • The biomass is also lysed by methods familiar to a person skilled in the art (mechanical or enzymatic lysis, see e.g. Birnboim and Doly, Nucleic Acids Research 7 (1979) 1513-1423) without addition of RNAse. It is possible to omit shaking out with phenol if the proteins are separated by chromatography on an anion exchanger. After lysis and separation of the insoluble components, preferably by centrifugation and filtration over a filter candle (5 μm pores), the cell supernatant is preferably firstly chromatographed on an anion exchanger to remove proteins. Suitable anion exchangers are anion exchangers based on agarose such as for example Q-Sepharose. Other suitable anion exchangers are based on polymethacrylate (Macroprep/Bio-Rad, Germany), polystyrene/divinylbenzene (Poros/Perseptive, HyperD/Biosepra, Source/Pharmacia) or silica gel on the surface of which diethylaminoethyl (DEAE) or dimethylaminoethyl (DMAE) groups are for example bound.
  • In order to optimize the purification effect, the nucleic acid is eluted by means of a high salt gradient e.g. NaCl gradient (preferably 0.65 mol/l-0.85 mol/l) in TE buffer. This surprisingly enables numerous impurities (RNA, protein) to be separated in one step.
  • It is also preferable to carry out an additional isopropanol/ethanol precipitation, preferably after the hydroxylapatite chromatography, to minimize the bioburden and for desalting. Subsequently the nucleic acid according to the invention can be bottled under sterile conditions.
  • The following examples describe the invention in more detail.
  • EXAMPLE 1 Isolation of Nucleic Acid from E. Coli Biomass
  • E. coli biomass containing plasmid DNA is lysed by an alkaline lysis and the released plasmid DNA is chromatographed over Q-Sepharose and HA-Ceramic. The eluate is desalted by an isopropanol/ethanol precipitation and concentrated and the plasmid DNA precipitate is resuspended in TE buffer.
  • Resuspension buffer: 50 mmol/l Tris/HCl, 10 mmol/EDTA-Na2, pH 8.0±0.2
  • Potassium acetate buffer: 3 mol/l potassium acetate buffer pH 5.5
  • 60 g biomass (wet, E. coli) from the fermenter is filled into depyrogenized centrifuge beakers. 750 ml resuspension buffer is added and it is stirred slowly (ca. 35 rpm) for at least 24 hours at 5±4° C. until the biomass is completely suspended. During this process the temperature of the suspension is slowly increased to 25° C.
  • 750 ml 0.2 mol/l NaOH/l % SDS is added to the suspension while stirring at ca 80 rpm and incubated for 5 minutes at 25° C. 750 ml potassium acetate buffer (see above) is added while stirring and the temperature of the biomass is lowered as rapidly as possible to 4° C.
  • The biomass is centrifuged for 30 minutes at 26000 xg and 4° C. The supernatant which contains the plasmid DNA is decanted and filtered clear over a 5 μm filter candle.
  • Chromatography on Q-Sepharose ff:
  • TE buffer: 10 mmol/l Tris-HCl, 1 mmol/l EDTA pH 8.0±0.2
  • Equilibration/wash buffer=gradient buffer A: 10 mmol/l Tris-HCl, 1 mmol/l EDTA, 0.65 mol/l NaCl pH 8.0±2.
  • Gradient buffer B: 10 mmol/l Tris-HCl, 1 mmol/l EDTA, 0.85 mol/l NaCl pH 8.0±0.2.
  • The decanted centrifuge supernatant is adjusted to 49-50 mS/cm conductivity by addition of ca. 350 ml TE buffer/l centrifugation supernatant and cooled to 5°±4° C. The whole chromatography is carried out at this temperature. The centrifugation supernatant is applied to the equilibrated column at 5-8 column volumes (CV)/h. Subsequently the column is washed at a flow rate of 5-8 CV/h with ca. 8 CV 10 mmol/l Tris-HCl, 1 mmol/l EDTA, 0.65 mol/l NaCl pH 8.0±0.2.
  • Elution
  • A gradient is applied to the column (5 CV buffer A, 5 CV buffer B) and the eluate is fractionated at a flow rate of 5-8 CV/h. The detection is carried out at 254 nm. The pre-peak (impurities) is separated from the main peak (plasmid DNA) by collecting the main peak from the increasing flank onwards in a separate vessel. The endotoxin content of the eluate is between 1200 and 12000 EU/mg plasmid DNA.
  • Chromatography on hydroxylapatite (HA ceramic)
  • The chromatography is carried out at 5±4° C.
  • Equilibration buffer: 0.1 mol/l potassium phosphate,
      • 6 mol/l urea pH 7.0±0.2
  • wash buffer 1: 0.15 mol/l potassium phosphate, 6 mol/l
      • urea pH 7.0±0.2
  • wash buffer 2: 0.02 mol/l potassium phosphate buffer
      • pH 7.0±0.2
  • elution buffer: 0.5 mol/l potassium phosphate pH 7.0±
      • 0.2
  • The detection is carried out at 254 nm with a UV detector/plotter unit. A 1% product solution (plasmid DNA) measured with a calibrated photometer is used as a calibration solution.
  • The Q-Sepharose® pool is adjusted to a final concentration of 1.1 mmol/l calcium chloride and applied to the equilibrated column at a flow rate of 5-8 CV/h.
  • Subsequently the column is consecutively washed at a flow rate of 5-8 CV/h with:
      • 1. 0.1 mol/l potassium phosphate, 6 mol/l urea pH 7.0±0.2, until absorbance is no longer detectable on the detector.
      • 2. 2-4 CV, 0.15 mol/l potassium phosphate, 6 mol/l urea pH 7.0±0.2
      • 3. 5 CV, 0.02 mol/l potassium phosphate pH 7.0±0.2
  • Following the wash steps it is eluted with 0.5 mol/l potassium phosphate buffer pH 7.0±0.1 at a flow rate of 5-6 CV/h.
  • The peak is collected, heated to 25° C. and 10% of it's volume of 4 mol/l KCl solution is added. Subsequently 0.7 parts by volume (relative to the volume of the eluate) of isopropanol is added, the solutions are mixed and incubated for 5-10 minutes at 25° C. It is centrifuged for 30 minutes at ≧20,000 xg, the plasmid DNA being in the precipitate.
  • 20 ml 70% ethanol is added to the precipitate and it is again centrifuged for 10-15 minutes at ≧20,000 xg at 4° C.
  • The precipitate which contains the plasmid DNA is resuspended in TE buffer (10 mmol/l Tris-HCl, 1 mmol/l EDTA pH 8.0+0.2) and adjusted to a plasmid concentration of 1 mg/ml. The endotoxin content is typically less than 0.06 EU/mg DNA and between 0.01 and 0.06 EU/mg DNA.
  • The endotoxin content is determined by adding a limulus amoebocyte lysate solution (LAL solution) to the solution to be examined. Endotoxins result in a gel formation in this mixture.
  • No gel formation should occur in the negative control preparations and in the positive control preparations as well as in the sample solutions supplemented with two λ control standard endotoxin a gel formation must occur.
  • The first dilution step of the solution of active substance for which these criteria apply and in which no gel formation occurs is used to calculate the endotoxin content of the solution of active substance solution according to the following formula:

  • E=V×λ(EE/ml)
      • E: endotoxin content
      • V: dilution factor
      • λ: lysate sensitivity (EE/ml)
    Example 2 Plasmid Preparation According to the State of the Art
  • The plasmid preparation is carried out analogously to Birnboim et al., Nucl. Acids Res . 7 (1979) 1513-1523 and Meth. Enzymol. 100 (1983) 243-255. Accordingly the bacterial cells are lysed in NaOH/SDS in the presence of RNase. It is centrifuged and the supernatant which contains the plasmid DNA is processed further. The supernatant is loaded onto a pre-equilibrated Qiagen® column.
  • The bacterial mass is resuspended in 4 ml buffer (100 μg/ml RNase A, 50 mmol/l Tris-HCl, 10 mmol/l EDTA, pH 8.0). 4 ml lysis buffer (200 mmol/l NaOH, 1% SDS) is added and it is incubated for 5 minutes at room temperature. Subsequently 4 ml neutralisation buffer (3 mol/l potassium acetate, pH 5.5) is, added and it is incubated for 15 minutes at 4° C. It is centrifuged for 30 minutes at 30,000 xg at the same temperature and the supernatant is processed further. A Qiagen® column is equilibrated with 4 ml equilibration buffer (750 mmol/l NaC1, 50 mmol/l MOPS, 15% ethanol, pH 7.0, 0.15% Triton®X 100) and the supernatant is applied to the column. It is washed with 1 mol/l NaC1, 50 mmol/l MOPS, 15% ethanol, pH 7.0 and eluted with 5 ml elution buffer (1.25 mol/l NaC1, 50 mmol/l Tris-HCl, 15% ethanol, pH 8.5).
  • The eluate is precipitated with isopropanol (0.7 vol) and centrifuged for 30 minutes at 15,000 xg at 4° C. The DNA pellet is washed in 70% ethanol and again centrifuged. Subsequently the pellet is resolubilized in 10 mmol/l Tris-HCl, 1 mmol/l EDTA, pH 8.0.
  • The endotoxin content of such a plasmid preparation is typically 300-3000 EU/mg. Using an endotoxin removal buffer according to WO 95/21177 and Qiagen news 1/96, p. 3-5 the endotoxin content can be further reduced to ca. 100 EU/mg.
  • LIST OF REFERENCES
    • Ausubel, F.M., et al. eds. (1991), Current Protocols in Molecular Biology, Wiley Interscience, New York
    • Birhboim, H.C. and Doly, J., Nucleic Acids Research 7 (1979) 1513-1523
    • Birnboim, H.C.., et al., Meth. Enzymol. 100 (1983) 243-255
    • Chandra et al., Analyt. Biochem. 203 (1992) 169-172
    • Cotten et al., Gene Therapy 1 (1994) 239-246
    • Dion et al., J. Chrom. 535 (1990) 127-147
    • European Patent EP-B 0 268 946
    • Fiedler, Lexikon der Hilfsstoffe für Pharmazie and Kosmetik und angrenzende Gebiete (Vol. 9, 3rd edition, 1989, Editio Cantor, GER)
    • Garger et al., Biochem. Biophys. Res. Comm. 117 (1983) 835-842
    • Johnson & Ilan, Analyt. Biochem. 132 (1983) 20-25
    • McClung & Gonzales, Analyt. Biochem. 177 (1989) 378-382
    • Protein Purification Methods, Ed. by Elv. Harries and S. Angal, Oxford University Press 1989, 238-244
    • QIAGEN NEWS 1/96, 3-5
    • QIAGEN Plasmid Handbook (Qiagen Inc., Chatsworth, U.S.A.)
    • Raymond et al., Analyt. Biochem. 172 (1988) 125-133
    • Sambrook, J. at al. (1989), Molecular Cloning: A Laboratory Manual, 2nd edition, Cold Spring Harbor Laboratory Press, New York, U.S.A.
    • WO 95/21177

Claims (22)

  1. 1. DNA preparation comprising a DNA, proteins in an amount of less than about 0.1% DNA and endotoxins in an amount of less than about 1 EU/mg DNA.
  2. 2. The DNA preparation of claim 1, comprising endotoxins of less than about 0.06 EU/mg DNA.
  3. 3. The DNA preparation of claim 1, comprising endotoxins of about 0.01 to 0.1 EU/mg DNA.
  4. 4. The DNA preparation of claim 1, wherein the DNA preparation is free of ethidium bromide, phenol, cesium chloride, octylphenolpoly(ethylene glycol ether)n detergents and MOPS buffer.
  5. 5. The DNA preparation of claim 1, wherein the DNA can be replicated in gram-negative bacteria.
  6. 6. The DNA preparation of claim 15, wherein the gram-negative bacteria is Escherichia coli.
  7. 7. The DNA preparation of claim 1, wherein the DNA is plasmid DNA.
  8. 8. The DNA preparation of claim 7, wherein the plasmid DNA is capable of replication.
  9. 9. A pharmaceutical composition suitable for gene therapy comprising a therapeutically effective amount of the DNA preparation of claim 5 and a pharmaceutically acceptable carrier.
  10. 10. The composition of claim 9, wherein the DNA preparation contains endotoxins in an amount of less than about 0.06 EU/mg DNA.
  11. 1. The composition of claim 9, wherein the DNA preparation contains endotoxins in an amount of about 0.01 to 0.1 EU/mg DNA.
  12. 12. The composition of claim 9, wherein the DNA is a plasmid DNA.
  13. 13. The composition of claim 12, wherein the plasmid DNA is encapsulated in liposomes.
  14. 14. A method for gene therapy of cystic fibrosis caused by the absence of a normal first gene or the presence of a defective second gene, comprising administering an effective amount of the DNA preparation of claim 18 to a patient in need thereof, wherein the plasmid DNA contains said normal first gene or a normal second gene corresponding to the defective second gene.
  15. 15. A process for making the DNA preparation of claim 1, comprising the following steps
    (a) providing gram-negative bacteria containing said DNA;
    (b) lysing said bacteria to obtain a lysate, wherein the lysate is a DNA-containing fraction and thereafter
    (c) chromatographing said DNA-containing fraction on hydroxylapatite in order to obtain said DNA preparation.
  16. 16. The method of claim 15, further comprising replicating said DNA in gram-negative bacteria after step (a) and before step (b).
  17. 17. The method of claim 16, further comprising transfecting the gram-negative bacteria with a cloning vector containing said DNA before step (a).
  18. 18. The method of claim 16, further comprising eluting said hydroxylapatite in step (c) with a solution of phosphate, citrate, sulfate or divalent metal ions to obtain said DNA preparation.
  19. 19. The method of claim 15, further comprising, after step (b) and before step (c), filtering the lysate to obtain a filtrate and fractionating said filtrate by gel filtration to obtain said DNA-containing fraction.
  20. 20. The method of claim 16, further comprising, after step (b) and before step (c), filtering the lysate to obtain a filtrate and fractionating said filtrate by gel filtration to obtain said DNA-containing fraction.
  21. 21. The method of claim 17, further comprising, after step (b) and before step (c), filtering the lysate to obtain a filtrate and fractionating said filtrate by gel filtration to obtain said DNA-containing fraction.
  22. 22. The method of claim 18, further comprising, after step (b) and before step (c), filtering the lysate to obtain a filtrate and fractionating said filtrate by gel filtration to obtain said DNA-containing fraction.
US13938398 1996-02-06 2013-07-10 Process for preparing purified nucleic acid and the use thereof Abandoned US20130315985A1 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
EP96101628.4 1996-02-06
EP96101628 1996-02-06
US09117537 US6750333B1 (en) 1996-02-06 1997-01-24 Process for preparing purified nucleic acid and the use thereof
PCT/EP1997/000321 WO1997029113A3 (en) 1996-02-06 1997-01-24 Process for preparing purified nucleic acid and the use thereof
US10771371 US20040209835A1 (en) 1996-02-06 2004-02-05 Process for preparing purified nucleic acid and the use thereof
US11389167 US20060165660A1 (en) 1996-02-06 2006-03-27 Process for preparing purified nucleic acid and the use thereof
US12627449 US20100074946A1 (en) 1996-02-06 2009-11-30 Process for preparing purified nucleic acid and the use thereof
US13197225 US20110293708A1 (en) 1996-02-06 2011-08-03 Process for preparing purified nucleic acid and the use thereof
US13545427 US20130004562A1 (en) 1996-02-06 2012-07-10 Process for preparing purified nucleic acid and the use thereof
US13938398 US20130315985A1 (en) 1996-02-06 2013-07-10 Process for preparing purified nucleic acid and the use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13938398 US20130315985A1 (en) 1996-02-06 2013-07-10 Process for preparing purified nucleic acid and the use thereof
US14277415 US9421279B2 (en) 1996-02-06 2014-05-14 Process for preparing purified nucleic acid and the use thereof

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US13545427 Division US20130004562A1 (en) 1996-02-06 2012-07-10 Process for preparing purified nucleic acid and the use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US14277415 Continuation US9421279B2 (en) 1996-02-06 2014-05-14 Process for preparing purified nucleic acid and the use thereof

Publications (1)

Publication Number Publication Date
US20130315985A1 true true US20130315985A1 (en) 2013-11-28

Family

ID=8222465

Family Applications (8)

Application Number Title Priority Date Filing Date
US09117537 Expired - Lifetime US6750333B1 (en) 1996-02-06 1997-01-24 Process for preparing purified nucleic acid and the use thereof
US10771371 Abandoned US20040209835A1 (en) 1996-02-06 2004-02-05 Process for preparing purified nucleic acid and the use thereof
US11389167 Abandoned US20060165660A1 (en) 1996-02-06 2006-03-27 Process for preparing purified nucleic acid and the use thereof
US12627449 Abandoned US20100074946A1 (en) 1996-02-06 2009-11-30 Process for preparing purified nucleic acid and the use thereof
US13197225 Abandoned US20110293708A1 (en) 1996-02-06 2011-08-03 Process for preparing purified nucleic acid and the use thereof
US13545427 Abandoned US20130004562A1 (en) 1996-02-06 2012-07-10 Process for preparing purified nucleic acid and the use thereof
US13938398 Abandoned US20130315985A1 (en) 1996-02-06 2013-07-10 Process for preparing purified nucleic acid and the use thereof
US14277415 Expired - Lifetime US9421279B2 (en) 1996-02-06 2014-05-14 Process for preparing purified nucleic acid and the use thereof

Family Applications Before (6)

Application Number Title Priority Date Filing Date
US09117537 Expired - Lifetime US6750333B1 (en) 1996-02-06 1997-01-24 Process for preparing purified nucleic acid and the use thereof
US10771371 Abandoned US20040209835A1 (en) 1996-02-06 2004-02-05 Process for preparing purified nucleic acid and the use thereof
US11389167 Abandoned US20060165660A1 (en) 1996-02-06 2006-03-27 Process for preparing purified nucleic acid and the use thereof
US12627449 Abandoned US20100074946A1 (en) 1996-02-06 2009-11-30 Process for preparing purified nucleic acid and the use thereof
US13197225 Abandoned US20110293708A1 (en) 1996-02-06 2011-08-03 Process for preparing purified nucleic acid and the use thereof
US13545427 Abandoned US20130004562A1 (en) 1996-02-06 2012-07-10 Process for preparing purified nucleic acid and the use thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14277415 Expired - Lifetime US9421279B2 (en) 1996-02-06 2014-05-14 Process for preparing purified nucleic acid and the use thereof

Country Status (10)

Country Link
US (8) US6750333B1 (en)
EP (1) EP0880536B2 (en)
JP (1) JP3442788B2 (en)
KR (1) KR100318808B1 (en)
CN (1) CN1121408C (en)
CA (1) CA2245576C (en)
DE (1) DE59709915D1 (en)
DK (1) DK0880536T4 (en)
ES (1) ES2195112T5 (en)
WO (1) WO1997029113A3 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110020924A1 (en) * 2008-04-30 2011-01-27 Gradalis, Inc. Highly pure plasmid dna preparations

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2746412B1 (en) 1996-03-21 1998-06-12 Rhone Poulenc Rorer Sa pharmaceutical quality plasmid DNA purification
US7026468B2 (en) * 1996-07-19 2006-04-11 Valentis, Inc. Process and equipment for plasmid purification
US7807822B2 (en) * 1996-08-01 2010-10-05 Robert Bridenbaugh Methods for purifying nucleic acids
DE19859703B4 (en) 1998-12-23 2009-10-29 Macherey, Nagel Gmbh & Co. Handelsgesellschaft A method for purifying nucleic acids as well as anion exchangers for carrying out this method
DE19903507A1 (en) 1999-01-29 2000-08-10 Roche Diagnostics Gmbh A process for the preparation of endotoxin or endotoxin-depleted nucleic acids and their use
EP1125943B1 (en) * 2000-02-16 2004-10-06 Macherey, Nagel GmbH &amp; Co. Handelsgesellschaft Process for the purification of nucleic acids and anion exchanger to carry out the process
GB0028361D0 (en) * 2000-11-21 2001-01-03 Glaxo Group Ltd Method of separating extra chromosomal dna from other cellular components
DE10238630A1 (en) * 2002-08-19 2004-03-04 Macherey, Nagel Gmbh & Co. Handelsgesellschaft A method for isolating biological macromolecules, and device for carrying out this method
EP1554398A4 (en) 2002-09-13 2005-12-14 Valentis Inc Apparatus and method for preparative scale purification of nucleic acids
EP1756178B1 (en) * 2004-04-02 2012-02-29 Nexttec GmbH Process for manufacturing a composite sorbent material for chromatographical separation of biopolymers
DK2027272T3 (en) * 2006-05-24 2016-03-14 Scarab Genomics Llc Plasmid DNA PREPARATIONS AND METHODS FOR THE MANUFACTURE OF SAME
US20090186396A1 (en) 2008-01-18 2009-07-23 Gagnon Peter S Enhanced purification of phosphorylated and nonphosphorylated biomolecules by apatite chromatography
CN102449150B (en) 2009-05-26 2015-12-02 欧洲生物技术股份有限公司 A method for producing and / or purified polynucleotides and apparatus and a product obtainable

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3639949A1 (en) 1986-11-22 1988-06-09 Diagen Inst Molekularbio A method for separating long chain nucleic acids
JPH01135792A (en) 1987-11-20 1989-05-29 Mitsui Toatsu Chem Inc Separation and purification of nucleic acid
US5561064A (en) * 1994-02-01 1996-10-01 Vical Incorporated Production of pharmaceutical-grade plasmid DNA
US5990301A (en) * 1994-02-07 1999-11-23 Qiagen Gmbh Process for the separation and purification of nucleic acids from biological sources
JP4113580B2 (en) * 1994-02-07 2008-07-09 キアゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング How to lose weight or remove endotoxin
WO1996002658A1 (en) 1994-07-15 1996-02-01 Merck & Co., Inc. A method for large scale plasmid purification
US5576196A (en) 1995-01-13 1996-11-19 Vical Incorporated Process for reducing RNA concentration in a mixture of biological material using diatomaceous earth
US6214586B1 (en) * 1997-12-08 2001-04-10 Genzyme Corporation Method for purifying plasmid DNA and plasmid DNA substantially free of genomic DNA
US6759394B2 (en) * 2001-07-26 2004-07-06 Board Of Supervisors Of La. State Un. & Agricultural And Mechanical College Cancer gene therapy based on translational control of a suicide gene

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110020924A1 (en) * 2008-04-30 2011-01-27 Gradalis, Inc. Highly pure plasmid dna preparations
US8969068B2 (en) 2008-04-30 2015-03-03 Gradalis, Inc. Processes for the preparation of highly pure plasmid compositions by enzymatic digestion of colanic acid

Also Published As

Publication number Publication date Type
JP3442788B2 (en) 2003-09-02 grant
WO1997029113A3 (en) 1997-10-02 application
DK880536T3 (en) grant
US20060165660A1 (en) 2006-07-27 application
EP0880536B2 (en) 2015-08-05 grant
KR100318808B1 (en) 2004-05-20 grant
ES2195112T3 (en) 2003-12-01 grant
WO1997029113A2 (en) 1997-08-14 application
CN1210541A (en) 1999-03-10 application
US9421279B2 (en) 2016-08-23 grant
US20130004562A1 (en) 2013-01-03 application
CN1121408C (en) 2003-09-17 grant
ES2195112T5 (en) 2015-10-15 grant
EP0880536A2 (en) 1998-12-02 application
US20110293708A1 (en) 2011-12-01 application
EP0880536B1 (en) 2003-04-23 grant
DK0880536T3 (en) 2003-08-11 grant
DK0880536T4 (en) 2015-09-07 grant
US20140287026A1 (en) 2014-09-25 application
DE59709915D1 (en) 2003-05-28 grant
JPH11509554A (en) 1999-08-24 application
CA2245576A1 (en) 1997-08-14 application
US20040209835A1 (en) 2004-10-21 application
US6750333B1 (en) 2004-06-15 grant
US20100074946A1 (en) 2010-03-25 application
CA2245576C (en) 2004-03-23 grant

Similar Documents

Publication Publication Date Title
Murray et al. Phage lambda receptor chromosomes for DNA fragments made with restriction endonuclease III of Haemophilus influenzae and restriction endonuclease I of Escherichia coli
Ditta et al. Broad host range DNA cloning system for gram-negative bacteria: construction of a gene bank of Rhizobium meliloti
Feliciello et al. A modified alkaline lysis method for the preparation of highly purified plasmid DNA from Escherichia coli
Diogo et al. Chromatography of plasmid DNA
US6355792B1 (en) Method for isolating and purifying nucleic acids
US5707812A (en) Purification of plasmid DNA during column chromatography
Prather et al. Industrial scale production of plasmid DNA for vaccine and gene therapy: plasmid design, production, and purification
Romanowski et al. Adsorption of plasmid DNA to mineral surfaces and protection against DNase I.
Levy et al. Biochemical engineering approaches to the challenges of producing pure plasmid DNA
Prazeres et al. Large-scale production of pharmaceutical-grade plasmid DNA for gene therapy: problems and bottlenecks
US5075430A (en) Process for the purification of DNA on diatomaceous earth
US6726907B1 (en) Purified adenoviral compositions
US4830969A (en) Process for the rapid and simple isolation of nucleic acids
Diogo et al. Purification of a cystic fibrosis plasmid vector for gene therapy using hydrophobic interaction chromatography
US5010183A (en) Process for purifying DNA and RNA using cationic detergents
US5155018A (en) Process and kit for isolating and purifying RNA from biological sources
US5792651A (en) Enhancement of the transfection efficiency of nucleic acids by using isopropanol in aqueous solutions
US6291248B1 (en) Nucleic acid purification and process
US5057426A (en) Method for separating long-chain nucleic acids
Eon-Duval et al. Purification of pharmaceutical-grade plasmid DNA by anion-exchange chromatography in an RNase-free process
WO1995006652A1 (en) Nucleic acid purification compositions and methods
WO1995034569A1 (en) Universal process for isolating and purifying nucleic acids from extremely small amounts of highly contaminated various starting materials
US6821757B2 (en) Rapid and simple process for isolation of circular nucleic acids
US6617108B1 (en) Methods and compositions for biotechnical separations using selective precipitation by compaction agents
WO2000034463A1 (en) Formulations and methods for isolating nucleic acids from any complex starting material and subsequent complex genetic analysis